This report provides all the information you require to better understand Genzyme and its partnering interests and activities over the past seven years.
This report provides all the information you require to better understand Genzyme and its partnering interests and activities over the past seven years.
Workers at Sanofi, a top big pharma company had a message for politicians at protests in Paris this month
French drugmaker Sanofi-Aventis has finally struck a deal to acquire U.S. biotech company Genzyme for $20.1 billion plus future payments based on the performance of Genzyme’s experimental multiple sclerosis drug, Lemtrada.
Despite runours, GSK’s Patrick Vallance, senior vice president of medicines discovery and development, says his company isn’t considering a bid for Genzyme
LabCorp, one of the US’ largest laboratory testing companies, will acquire the genetic testing business from Genzyme for $925 million in cash.
It looks as if Sanofi-Aventis has made a concession.
Sorry, your search returned no results.
Genzyme biotech deals AskBio in a licensing agreement for duplex gene therapy vector technology.
Genzyme and Veracyte announced a global co-promotion partnership to provide a comprehensive solution for thyroid patients. The arrangement will give patients worldwide increased access to an advanced personalized medicine solution for improved diagnosis of thyroid nodules, and the potential to significantly reduce the number of unnecessary thyroidectomies.
Genzyme Corporation today announced that it has completed the sale of its diagnostic products business to Sekisui Chemical Co., Ltd. for $265 million in cash.
Laboratory Corporation of America® Holdings has announced the successful completion of its acquisition of Genzyme Genetics, a business unit of Genzyme Corp., in an all cash transaction valued at $925 million. Net of expected income tax benefits, less acquisition-related expenses, the acquisition has a net cash cost to LabCorp of approximately $795 million.